News

CVT-301 provides immediate onset of a large and precise dose of L-dopa. The Phase 2a study is a randomized, placebo-controlled, single dose, cross-over design that will feature the

The total acquistion value is considered to be $312m and around $114m based on certain pre-determined milestones which also includes revenue targets. As of 31March 2012, US-based OraPharma’s

The licence will help Life Technologies to expand its products and services for the iPS cell research community. The agreement also allows Life Technologies leverages to sell iPS

Shanghai Clinical Research Centre(SCRC), Quintiles’ strategic partner in the China-based lab initiative, will provide lab testing services to customers as part of the agreement. Quintiles will invest $14m

The trial, which involves 96 patients, is being carried out under an agreement with The Centre Hospitalise Universities dangers ("CHI dangers"). The 18-month, double-blind, placebo-controlled study will be

According to the 2011 CRN Consumer Survey on Dietary Supplements, overall, 69% of US adults use dietary supplements. Nouveau Life CEO Melissa Walker said the data point alone

The aim of the trial will be to know whether closed oregovomab in relation with front-line chemotherapy will generate the same or an improved immunity and clinical response.

Under the agreement Clarity’s PET based companion diagnostics and radio-immunotherapeutics development program will receive cGMP chemistry manufacturing,scale up and aseptic fill/finish services and analytical support from Dalton Pharma.

The Company has completed testing and released the final drug product of sparvax for further clinical evaluation. PharmAthene’s rPA technology platform uses E.Coli, a technology which increases manufacturing